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Abstract
Classified as benign central nervous system (CNS) tumors, pituitary adenomas account for 10% of diagnosed intracranial
neoplasms. Although surgery is often curative, patients with invasive macroadenomas continue to experience significant
morbidity and are prone to tumor recurrence. Given the identification of human brain tumor-initiating cells (TICs) that
initiate and maintain tumor growth while promoting disease progression and relapse in multiple CNS tumors,
we investigated whether TICs also drive the growth of human pituitary adenomas. Using a nanoString-based
80-gene custom codeset specific for developmental pathways, we identified a differential stem cell gene expression
profile within human pituitary adenomas. Prospective functional characterization of stem cell properties in patient-derived
adenomas representing all hormonal subtypes yielded a subtype-dependent self-renewal profile, which was enriched
within the CD15+ cell fraction. The tumor-initiating capacity of CD15high adenoma cells was assayed in comparison to
CD15low adenomas using in vivo limiting dilutions, which maintained the rare frequency of TICs. Repeated analyses using
sorted cell populations for CD15+ TICs compared to CD15- adenoma cells provided further evidence of xenograft tumor
formation to support CD15+ cells as putative pituitary adenoma-initiating cells (PAICs). The clinical utility of our findings
was established through in silico analyses and comparative gene expression profiling of primary and recurrent pituitary
adenomas. CD15 was enriched in recurrent adenomas, which was validated using routine clinical immunohistochemistry
in a limited number of samples. Our work reports the first prospective identification of human PAICs using CD15. Patients
with CD15high adenomas may therefore benefit from more aggressive surgical interventions and chemo/radiotherapy.
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Introduction
Inter- and intratumoral heterogeneity are hallmark fea-
tures of human central nervous system (CNS) tumors, as
distinct molecular subgroups and cell populations have
been described in tumors that otherwise appear histologi-
cally homogeneous [9, 29, 31]. Pituitary adenomas (PAs)
account for 10% of diagnosed intracranial neoplasms and
have been described in up to 25% of adult autopsies [2].
While surgery is often curative, patients with invasive
macroadenomas (>10 mm) continue to experience signifi-
cant morbidity due to the overexpression of pituitary
hormones and compression of surrounding brain struc-
tures [2]. The anterior pituitary gland is comprised of
multiple cell types that secrete unique hormones includ-
ing, prolactin (PRL), growth (GH), adenocorticotropic
(ACTH), luteinizing (LH), follicle-stimulating (FSH), and
thyroid-stimulating (TSH) hormone [2]. These diverse cell
types and their corresponding hormone expression
profiles have traditionally been used to subgroup PAs for
targeted therapies [2]. A subset of tumors that are non-
functional or do not secrete hormones are termed null cell
(NC) adenomas [2]. While the multicellular milieu and
hormonal subtypes of these tumors contribute to intra-
and intertumoral heterogeneity, respectively, the initiation
and maintenance of human PAs remains poorly under-
stood [3, 19, 35, 36].
Contemporary frameworks of cancer recognize a rare
population of cells, termed tumor-initiating cells (TICs)
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that are able to initiate and maintain tumor growth [13].
By applying culture conditions and assays used to
characterize normal neural stem cells (NSCs), we were
among the first researchers to identify such cells from a
variety of human brain tumors termed brain tumor-
initiating cells (BTICs) [25, 26]. While TICs have tradition-
ally been isolated and characterized using flow cytometric
cell-sorting, no study has prospectively isolated and charac-
terized TICs in human PAs [1, 3, 5–7, 10, 19, 35]. A unique
property by which TICs may induce oncogenesis is self-
renewal [23], defined as the ability of the parental cell to
generate an identical daughter cell and a second daughter
cell of the same or different phenotype and genotype [24].
Enhanced self-renewal as a mechanism of tumor initiation
in PAs has been demonstrated with the growth of plurihor-
monal adenomas following the targeted expression of onco-
genes in murine pituitary stem cells [1, 5, 7, 10]. The
spontaneous PAs that develop in Rb+/− mice provide fur-
ther evidence for a hierarchical distribution of cells in these
tumors [5]. Cells prospectively isolated using the surface
marker Sca1 in this model represent a rare fraction of the
bulk tumor with an enriched self-renewal capacity and
tumor initiation potential in xenografts. Whereas TICs have
been reliably isolated and characterized in murine models
of PA [1, 5, 7, 10], our insight into human PAICs has been
limited to observational studies in which adenoma cells are
cultured as tumor spheres in serum-free media or immuno-
histochemical staining for the expression of putative regula-
tors of self-renewal [3, 19, 35, 36]. While these studies may
suggest an active TIC population in human PA, they have
largely been limited to a minority of hormonal subtypes
and have yet to perform in vivo limiting dilution assays to
assess the frequency of TICs in human PA. Consequently, a
functional validation of putative markers of human PAICs
may yield a robust profile of these cells within treatment-
refractory adenomas.
In this study, we report the use of a nanoString-based
80-gene custom codeset specific for developmental path-
ways to identify differentially expressed TIC markers
and self-renewal genes in primary and matched-recurrent
PAs. Prospective flow cytometric analysis on one hit,
CD15, in additional PAs representing all functional and
non-functional subtypes reliably demonstrated CD15 as a
marker of adenomas with an enriched tumor sphere for-
mation capacity. Cell-sorting for CD15 further established
CD15+ cells as putative PAICs as these cells displayed a
marked sphere formation phenotype and expression of
genes associated with the developing pituitary when com-
pared to CD15- cells. The tumor-initiating capacity of
PAICs from CD15high adenomas along with CD15+
adenoma cells was assayed using in vivo limiting dilutions,
which maintained the rare frequency of PAICs. We
further establish the clinical utility of our findings by
demonstrating CD15 to be enriched in residual/recurrent
adenomas by in silico analyses, gene expression profiling,
and a retrospective cohort of patient samples immuno-
stained for CD15. Our work reports the first prospective
identification of human PAICs using CD15. Patients with
CD15high adenomas may therefore benefit from more
aggressive surgical interventions and chemo/radiotherapy.
Materials & methods
nCounter System (NanoString) gene expression profiling
Fourteen pituitary adenomas of varying subtypes (Table 1,
PA1-14) along with 2 primary and matched-recurrent
pituitary adenomas (Table 2) were used to isolate RNA
from formalin-fixed paraffin-embedded (FFPE) tissue
using Roche High Pure FFPE RNA micro kit. Exactly
250 ng of RNA was run for each patient sample. Analysis
using nCounter Gene Expression system was conducted
at McMaster University’s core facility. A custom codeset
synthesized by nCounter (NanoString Technologies,
Seattle, WA, USA) was designed. The recommendations
outlined by NanoString Technologies were all followed
regarding mRNA sample preparation, hybridization, de-
tection and scanning, and data normalization.
Dissociation of primary human pituitary adenoma tissue
and tumor sphere culture
Human pituitary adenoma samples (Table 1) were
obtained from consenting patients, as approved by the
Hamilton Health Sciences/McMaster Health Sciences
Research Ethics Board. Briefly, samples were dissociated
in artificial cerebrospinal fluid containing 0.2 Wunisch
unit/mL Liberase Blendzyme 3 (Roche filtered through
70 μm cell strainer. Tumor cells were resuspended in
tumor sphere medium consisting of a chemically defined
serum-free tumor sphere medium (TSM), and plated in
an ultra-low attachment plate (Corning). The compo-
nents of our complete TSM per 500 mL include: Dulbec-
co’s modified Eagle’s medium/F12 (450 mL; Invitrogen),
N2-supplement (5 mL; Invitrogen), HEPES (5 mL;
Wisent), glucose (3 g; Invitrogen), N-acetylcysteine (60
μg/mL; Sigma), neural survival factor-1 (10 mL; Lonza),
epidermal growth factor (20 ng/mL; Sigma), basic fibro-
blast growth factor (20 ng/mL; Invitrogen), leukemic
inhibitory factor (10 ng/mL; Cehmicon). All PAIC
patient isolates used for experimentation were not
renewable cell lines, but rather minimally cultured cell
isolates (24 h to <1 week) within tumor sphere condi-
tions to select for TICs.
Secondary sphere formation assay
After primary tumor sphere formation was noted,
spheres were dissociated to single cells and replated in
TSM as previously described [26]. Secondary sphere for-
mation was calculated from the number of spheres
formed from 2000 dissociated single cells.
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Quantitative real-time–polymerase chain reaction
Total RNA from samples was isolated using the Norgen
RNA extraction kit (Biotek) and reverse transcribed
using qScript cDNA Super Mix (Quanta Biosciences)
and a C1000 Thermo Cycler (Bio-Rad). qRT-PCR was
performed using the CFX96 (Bio-Rad) with SsoAdvanced
SYBR Green (Bio-Rad) using gene specific primers. Data
were presented as the ratio of the gene of interest to
GAPDH (glyceraldehyde-3-phosphate dehydrogenase) as
control using 2ΔCT. The program Primer3 (NCBI, Primer-
BLAST, http://www.ncbi.nlm.nih.gov/tools/primer-blast)
was used to design primer sequences provided in Table 3.
Flow cytometric cell sorting
Primary pituitary adenoma tumor spheres were dissoci-
ated to single cell suspension. Stemness marker expression
was assessed using flow cytometric sorting (MoFlo XDP)
using PE-labeled anti-CD15 (1:10, Beckman Coulter Inc.,
Brea, CA, USA), APC-labeled anti-CD133 (1:10, Miltenyi
Biotec GmbH, Bergisch Gladbach, Germany), and v450-
labeled anti-Sox2 (1:20, BD Biosciences, San Jose, CA,
USA) antibodies. The percentage expression of CD15 for
each group of unsorted cells and purities for CD15
+/CD15- sorted cells were determined. The appropriate
isotype control served as the negative control.
Table 2 Clinico-pathological demographics of matched primary
and recurrent pituitary adenomas
Sample ID Gender Age Adenoma Subtype Time to
Recurrence
PA23 (Primary 1) F 49 Null Cell 7 years
PA24 (Recurrent 1) 56 TSH, FSH/LH (focal)
PA25 (Primary 2) M 32 GH/PRL 3 years
PA26 (Recurrent 2) 35 GH/PRL
PA pituitary adenoma, M Male, F Female, GH Growth Hormone, PRL Prolactin,
FSH Follicle-Stimulating Hormone, LH Luteinizing Hormone, TSH
Thyroid-Stimulating Hormone
Table 1 Pituitary adenoma stem cell patient isolates: Clinico-pathological data
Sample ID Gender Age Adenoma Subtype CD15% CD133% Sox2%
PA1 M 69 GH 15.92 1.82 3.55
PA2 M 72 ACTH 10.25 89.75 12.82
PA3 M 35 GH 75.15 1.2 9.53
PA4 F 66 FSH/LH 83.46 16.55 4.54
PA5 M 76 GH 7.12 0.54 3.11
PA6 M 53 FSH/PRL 4.11 23.13 11.35
PA7 F 26 GH/PRL 2.59 47.98 28.36
PA8 F 52 Null Cell 62.71 1.07 2.24
PA9 F 76 LH 4.51 13.11 9.23
PA10 F 60 Null Cell 80.72 19.29 2.74
PA11 M 80 Null Cell 84.22 1.99 2.05
PA12 M 83 Null Cell 14.98 11.32 4.52
PA13 M 80 Null Cell 72.70 1.52 2.74
PA14 M 48 GH/PRL 7.06 3.92 6.63
PA15 M 51 GH/PRL 3.11 1.42 3.13
PA16 M 70 Null Cell 53.12 0.45 1.19
PA17 M 42 GH 99.56 0.47 19.24
PA18 M 64 Null Cell 7.23 12.21 7.31
PA19 M 52 Null Cell 98.86 0.96 15.07
PA20 M 72 GH 9.86 2.26 1.78
PA21 F 71 Null Cell 62.12 1.11 1.42
PA22 F 71 Null Cell 44.15 1.78 2.51
PA pituitary adenoma, M Male, F Female, GH Growth Hormone, ACTH Adrenocorticotropic Hormone, PRL Prolactin, FSH Follicle-Stimulating Hormone, LH
Luteinizing Hormone
Table 3 qRT-PCR primers
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In vivo PAIC injections and H&E staining of xenograft
tumors
In order to achieve a human-mouse xenograft model,
immunodeficient NOD-CB17-SCID mice (n = 16) were
used for optimal engraftment of human cells according
to Research Ethics Board-approved protocols. Due to
the susceptibility of these mice to infection, all proce-
dures were performed in a designated clean room and
within a BSL-2 hood. Cells to be injected were re-
suspended in 10 μL of PBS. Once mice were anesthesized,
they were secured into a stereotactic frame. Using a cotton
swab, the head of the mouse was cleaned with surgical
detergent followed by water and then a providone-iodine
surgical scrub. A sagittal cut was then performed down the
midline of the mouse’s head using a scalpel. The cut ran
from between the eyes to the point that is equidistant from
both mouse ears. The periosteum of the skull was removed
by scraping with the scalpel. Next, the sagittal and coronal
sutures were located and the point located 2 mm posterior
to the coronal suture and 3 mm to the right of the sagittal
suture was identified. A burr hole was drilled at this point
by tapping the drill bit lightly against the skull. The drill
was applied until a reddish area was visible or until a
Hamilton syringe could penetrate through the remaining
skull. The 10 μL PBS solution containing tumor cells was
injected using a Hamilton syringe at a depth of 3 mm of
the needle head into the burr hole at an angle of either 90°
or 60° from horizontal. The injection of cells was performed
in one smooth, uninterrupted motion. Mice were injected
with biological replicates (n = 4) consisting of three dilu-
tions (1×105, 5×104, 1×104 single-cell suspensions). 5 add-
itional mice were also injected with PAICs sorted for CD15
(1 CD15+ mouse at 5x104 cells and 2 CD15- mice, each at
5×104, 1×105). The end of the syringe was then tapped
three times to ensure that droplets remained in the brain
and were not displaced during the removal of the Hamilton
syringe. The wound was then sutured with 2–3 stitches
using a simple interrupted technique. An additional two
extra throws after the initial knot had been tied were also
used prior to cutting off any excess suture thread. 1 mL of
sterile 0.9% Sodium Chloride was subcutaneously injected
by inserting the syringe into the scruff of the neck or the
gluteal region of the mouse. 0.5 mL of buprenorphine
(Temgesic) was also injected subcutaneously using the
same method and location. The mouse was then placed in
a recovery cage near a heat source until it awoke. On the
first day following surgery, mice were injected subcutane-
ously with 1 mL of sterile 0.9% Sodium Chloride and
0.5 mL of buprenorphine. Mice were then observed until
experimental endpoint. All resulting human tumor xeno-
grafts were fixed, embedded in paraffin for hematoxylin
and eosin (H&E) staining; images were taken using an
Aperio Slide Scanner and analyzed using ImageScope
v11.1.2.760 software (Aperio).
In situ bioinformatic analysis
All data was publicly available and downloaded from the
gene expression omnibus (http://www.ncbi.nlm.nih.gov/
geo/). A pituitary tumor cohort (GSE26966) was used to
evaluate the expression of stemness genes [16]. This cohort
is composed of 23 samples comprising 8 normal pituitary
samples, 9 pituitary tumors, and 5 pituitary tumor reccur-
ences. Each sample underwent global gene expression
profiling with the Affymetrix U133 Plus 2.0 microarray
platform. The raw intensity files (.CEL) comprising each
dataset were download and normalized using the Robust
Multichip Algorithm (RMA) to generate probeset inten-
sities [12]. When multiple probesets mapped to the same
gene, the median intensity probeset value was taken to rep-
resent gene intensity. T-tests were used to compare gene
expression between normal pituitaries and pituitary tumors,
as well as recurrent and primary pituitary tumors.
CD15 immunohistochemical staining of primary and
recurrent pituitary adenoma
Briefly, formalin-fixed paraffin embedded patient blocks
were cut at 5 μm sections and immunostained using the
avidin-biotin-peroxidase complex method with diamino-
benzidine as the chromogen. The primary antibodies
used were mouse monoclonal antibodies against CD15
(1:100; Dako, Mississaugua, ON, Canada).
Statistical analysis
For all in vitro studies, biological replicates from at least
three tumors are compiled for each experiment in order
to achieve statistical power; unique samples were not
pooled before analyses. Data represent mean±s.e.m., n
values are listed in figure legends. Student’s t-test analyses
were performed accordingly, using the Prism 4.03 software
package (GraphPad Software). The independent Student’s
t-test was used to compare the continuous variables
between two groups. The level of statistical significance was
set at 0.05 for all tests.
Results
Human pituitary adenomas express stemness genes and
contain a distinct cell population capable of sphere
formation
Multiple reports have consistently shown genes that
regulate key stem cell properties such as self-renewal
and differentiation, termed stemness genes, to contribute
to intra- and intertumoral heterogeneity [23, 28], while
predicting clinical variables such as treatment response
and overall survivorship [13]. However, no such investiga-
tions have been performed in human PAs. The successful
detection of stemness genes in pituitary adenomas has
previously been hampered by limitations in robust, cost-
effective gene expression platforms capable of detecting
genes expressed at the resolution of a single transcript, as
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might be the case with stemness genes, which are exclu-
sively expressed in rare TICs [15]. Using a nanoString-
based 80-gene custom codeset, we determined the differen-
tial stemness gene expression profile across 14 human PAs
(Table 1, PA 1–14) representing the most common hormo-
nal subtypes (Fig. 1a). Interestingly, our analyses revealed
significant intertumoral heterogeneity across PAs, indi-
cating a spectrum of stemness in which some PAs
retained a primitive gene expression network, while
others displayed a less primitive genotype.
In order to functionally validate our observed spectrum
of genetic stemness, we minimally cultured primary
human PAs in tumor sphere media conditions as previ-
ously described [25]. Sphere formation, a function of clon-
ally derived TICs, was observed in all primary adenoma
subtypes to varying degrees (Fig. 1b), which supported our
observed genetic heterogeneity in stemness. The most
compelling evidence for cancer cell heterogeneity within a
given tumor is obtained by using cell surface markers to
prospectively isolate distinct subpopulations of malignant
cells with corresponding phenotypic diversity. However,
the utility of surface markers in dissecting intratumoral
heterogeneity is complicated by the reported ability of
certain cancer cells to reversibly transition between
phenotypic states [8]. Regardless of the presence of a rigid
hierarchy, determinants of stemness have been shown to
contribute to treatment failure, irrespective of whether
these determinants are present within a dynamic or static
population. We therefore performed flow cytometric
characterization of 22 human PAs for CD15, CD133, and
Sox2 (Table 1, Additional file 1: Figure S1). Although, both
CD15 [22, 27, 32] and CD133 [25, 26] have previously
been shown to identify TICs in highly aggressive and
malignant brain tumors, their prospective flow cytometric
characterization of putative PAICs has not been described.
Our analyses across multiple hormonal subtypes consist-
ently characterized a distinct CD15+ population of cells
within human PAs, while CD133 marked a negligible cell
fraction (Fig. 1b). Given the presence of a differential
stemness gene expression profile, coupled with the
capacity for sphere formation and expression of putative
TIC markers, our data supports the application of the TIC
model for investigating the biological heterogeneity ob-
served in human PAs.
Fig. 1 Human pituitary adenomas express self-renewal genes and contain a distinct cell population capable of sphere formation. a Differential
stem cell gene expression profile of 14 human pituitary adenomas using a nanoString-based 80-gene custom codeset. b Representative photomicrograph
of human PAICs and flow cytometric plots of CD15 and CD133 expression across adenoma subtypes. (×100, Scale bar = 100 μm)
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Developmental genes of the normal pituitary are
enriched in human pituitary adenomas, especially those
adenomas with increased sphere formation
Since several brain tumors are comprised of a function-
ally heterogeneous population of cells that perpetuate
tumor growth through unregulated self-renewal [13, 23],
we performed functional assays to assess the subtype-
dependent sphere formation rate within PAs. The rate of
secondary tumor sphere formation was much lower in
all PA subtypes when compared to highly aggressive and
malignant tumors such as glioblastoma, medulloblastoma,
and brain metastasis (data not shown). However, we did
observe a wide distribution in the rate of secondary tumor
sphere formation across multiple subtypes, particularly,
GH-secreting and null cell adenomas (Fig. 2a). While the
number of adenomas within each subgroup in our
analyses was reflective of their prevalence in the general
population, we were limited to a single tumor for a small
number of subtypes (ACTH, FSH/LH, FSH/PRL, LH),
making it difficult to comprehensively interrogate the
spectrum of secondary sphere formation rates among
these tumors. In order to supplement our sphere forma-
tion assays, we investigated the gene expression profile of
Pax7 and Sox2 within our PA cohort. Both, Pax7 [10] and
Sox2 [1] have been shown to identify unique primitive cell
populations in the developing murine pituitary with the
potential for initiating and maintaining tumorigenesis
following transformation events. Both genes contained an
assorted expression profile across subtypes (Fig. 2b, c,
Additional file 1: Figure S1), further highlighting the
significant inter- and intrasubtype heterogeneity within
PAs. Given the wide distribution in sphere formation and
gene expression profile of putative PA-specific stemness
genes, Pax7 and Sox2, we sought to assess the secondary
sphere formation rate of Pax7high and Sox2high PAs com-
pared to Pax7low and Sox2low PAs, respectively. Using a
median cutpoint based on the gene expression values of
Pax7 and Sox2, we plotted PAs according to the high or
low expression of these genes relative to the rate of
secondary tumor sphere formation (Fig. 2d, e). An overall
trend in keeping with an increased sphere formation
among Pax7high and Sox2high PAs was detected, which
fostered the development of our framework in which a
distinct population of cells within PAs across all subtypes
have an enhanced ability for sphere formation, which may
be regulated by the re-expression of genes present during
pituitary development.
CD15 enriches for pituitary adenoma-initiating cells
While the ability of human PA cells to be cultured as
tumor spheres and the expression of genes associated with
ontology have previously been described [3, 19, 35, 36],
Fig. 2 Human pituitary adenomas express genes in keeping with the developing pituitary and contain a distinct cell population capable of sphere
formation. a Sphere formation capacity of adenomas is dependent on subtype. b Pax7 and (c) Sox2, genes activated during development of the
pituitary gland are preferentially expressed in PAICs irrespective of subtype. Both, (d) Pax7high and (e) Sox2high tumors display an increased capacity for
sphere formation when compared to Pax7low and Sox2low adenomas
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the prospective flow cytometric characterization and isola-
tion of putative PAICs based on cell surface marker
expression has yet to be performed. Such assays provide
valuable evidence in support of heterogeneous cell-cell in-
teractions that may be critical for the evolution of tumors
from ontology to oncology and throughout the course of
therapy. We performed flow cytometric characterization
of CD133 [25, 26], Sox2 [30], and CD15 [22, 27, 32], three
markers that have reproducibly been shown to mark TICs
in a number of pediatric and adult brain tumors (Fig. 1b,
Table 1). Since our work consistently showed CD15 to
identify a unique fraction of PA cells, we assessed the
genetic and functional cellular differences between
CD15high and CD15low adenomas. Using a median cutpoint
to distinguish between CD15high (n = 11, PA 3, 4, 8, 10, 11,
13, 16, 17, 19, 21, 22) and CD15low (n = 11, PA 1, 2, 5, 6, 7,
9, 12, 14, 15, 18, 20) adenomas, we investigated the expres-
sion of developmental genes Pax7 and Sox2, which we
found to correlate with an increased rate of secondary
sphere formation (Fig. 2d, e). Both, Pax7 (Fig. 3a, P < 0.005)
and Sox2 (Fig. 3b, P < 0.001) were significantly enriched in
CD15high adenomas when compared to CD15low tumors.
Therefore, we hypothesized that CD15 may mark a unique
fraction of cells with an enhanced potential for self-renewal
and tumor initiation. Given the technical challenges in cul-
turing primary human PAs combined with flow cytometric
cell-sorting, a limited number of PAs (n = 2, PA 3, 22) were
sorted for CD15+ and CD15- cells (Fig. 3c). Sorted cells
were plated for secondary sphere formation assays, which
yielded a significant difference in the frequency of spheres
in CD15+ PAICs compared to CD15- cells (Fig. 3d, e, P <
0.01). Similarly, CD15high (n = 5) adenomas maintained a
much higher sphere formation capacity when compared to
CD15low (n = 5) tumors (Fig. 3f, P < 0.01), further demon-
strating the presence of a highly tumorigenic regulatory
network within CD15+ PAICs. Collectively, our data
Fig. 3 CD15 enriches for pituitary adenoma-initiating cells. Pituitary developmental genes (a) Pax7 (n= 22, P< 0.005) and (b) Sox2 (n= 22, P< 0.001) are
highly expressed in CD15high adenomas compared to CD15low tumors. c Representative flow cytometric plot for enrichment of CD15+
PAICs. d Photomicrograph comparing sphere formation in CD15+ PAICs and CD15- cells (×100, Scale bar = 100 μm). e CD15+ PAICs
maintain a higher sphere formation capacity when compared to CD15- cells (n = 2, P < 0.01). f CD15high pituitary adenomas contain a
higher sphere formation rate when compared to CD15low tumors, irrespective of adenoma subtype (n = 10, P < 0.01)
Manoranjan et al. Acta Neuropathologica Communications  (2016) 4:125 Page 7 of 13
illustrates the prospective isolation and characterization of
a distinct cell population in human PAs, which may con-
tribute to intratumoral heterogeneity but also distinguish
tumors based on their relative expression of CD15.
CD15high adenomas and CD15+ pituitary adenoma-
initiating cells are capable of tumor initiation in
human-mouse xenografts
The most definitive method to assess the presence
and function of PAICs is to carry out in vivo xeno-
transplantation assays and thereby quantify the fre-
quency of tumor initiation [26]. Given the limited
proliferative potential of human PA primary cultures,
we initially compared the tumor-initiating capacity
across the unsorted bulk population of cells isolated
from CD15high and CD15low adenomas. Three limiting
dilutions (1×105, 5×104, 1×104) were used for intracranial
injections of two biological replicates, each for CD15high
(PA 19, 21) and CD15low adenomas (PA 18, 20).
Interestingly, no tumors were formed from CD15low
adenomas from all three dilutions (Fig. 4b). In con-
trast, CD15high adenomas generated small lesions at
the single dilution of 1×105 cells (Fig. 4a), in keeping
with the rare frequency of PAICs in benign brain
tumors. While this data informs us of an increased
capacity for tumorigenesis within CD15high adenomas,
the gold standard for identifying and thoroughly
characterizing TICs is through the prospective flow
cytometric cell sorting of a putative TIC marker. We
therefore set out to perform the first xenotransplantation
assay in sorted human PA cells. Since cell-sorting for in
vivo xenotransplantation assays requires a significant
number of viable cells to ensure adequate engraftment, we
were limited to a single biological replicate (PA 22) for this
proof of principle experiment. In order to assess the
frequency of PAICs in CD15+ and CD15- cells, we
performed a limiting dilution consisting of 5×104 (n = 3)
and 1×105 (n = 2) cells. We observed robust, invasive,
Fig. 4 CD15+ pituitary adenoma-initiating cells maintain their tumor initiation potential in human-mouse xenografts. Representative H/E stain of
pituitary adenoma xenografts generated from a limiting dilution of CD15high and CD15low adenomas demonstrate (a) tumors with a glandular morphology
from CD15high adenomas at a dilution of 1×105 cells (n = 2, ×200) compared to (b) no apparent tumor formation in CD15low xenografts at all
dilutions (n = 2, ×200). Whole-mount H/E stain of xenografts show (c) CD15+ adenoma cells to result in significant tumor growth (n = 1, ×4),
whereas (d) CD15- adenoma cells are unable to initiate tumor formation (n = 2, ×4). e Low (×50) and (f) high power (×200) images of CD15+
PAIC-generated xenografts
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multi-focal tumors with 5×104 CD15+ cells (Fig. 4c). In
contrast, no tumors were generated with 5×104 and 1×104
CD15- cells (Fig. 4d) and two additional mice injected
with 5×104 and 1×104 CD15- cells were still alive at the
time of writing this manuscript. Further characterization
of tumors initiated by CD15+ PAICs demonstrated signifi-
cant mitoses and nuclear atypia (Fig. 4e, f ), in support of
CD15 functioning as a highly tumorigenic cell population
in human PAs. Overall, our data support the enrichment
of PAICs in CD15high adenomas, which is made apparent
following cell sorting for CD15+ PAICs.
Xenografts generated from CD15+ pituitary adenoma-
initiating cells maintain multi-lineage specification in vivo
An exhaustive immunohistochemical analysis was per-
formed to further characterize the tumors generated
from CD15+ PAICs. Given that the histological
subtype of the original patient sample was a null cell
adenoma (PA22), the lack of immunoreactivity within
the xenograft for our pituitary hormone panel was
expected (data not shown). Both samples were also
immunonegative for GFAP, alpha-smooth muscle
actin, EMA, and TTF1 (data not shown). In support of
their neuroendocrine origin the primary patient
sample and xenograft were both immunopositive for
synaptophysin (Fig. 5a) and CD56 (Fig. 5b). However,
desmin (Fig. 5c) and myogenin (Fig. 5d) were exclu-
sively and unexpectedly expressed in the xenograft,
highlighting the potential for multi-lineage differenti-
ation within CD15+ PAICs. Interestingly, cytokeratin
maker (AE1/AE3) expression was present in the
original patient sample but was not detected in the
xenograft (Fig. 5e), indicating the possibility of clonal
divergence between the primary patient tumor and
corresponding xenograft. Niche-specific effects may
also contribute to these surprising results as our intra-
cranial xenografts were derived from injecting cells
into the frontal lobe and not the mouse pituitary.
Nevertheless, previous reports of murine pituitary
folliculostellate cells having the ability to differentiate
into multinucleated tubular cells with immunoreac-
tivity for myogenin [11, 17], raises the possibility of
CD15+ PAICs representing a putative folliculostellate
cell despite the lack of S100 expression in our
xenografts.
CD15 is highly expressed in recurrent adenomas when
compared to matched primary samples
While the identification of TICs has enhanced our con-
ceptual understanding of the complex biological networks
that initiate and maintain brain tumorigenesis, the clinical
utility in identifying of these cells is largely dependent on
their therapeutic targeting and use in prognostication as a
measure of overall outcome. Since prior work has
demonstrated an increasing TIC frequency to be associ-
ated with tumor aggressiveness [25, 26] and poor patient
outcome [14, 20, 21], we investigated the enrichment of
CD15 in recurrent/residual PAs. Given that recurrence
was defined as reonset of clinical symptoms or radio-
logical tumor growth >25%, we combined tumor recur-
rence and progression. We specifically assessed two
primary and matched recurrent samples in which there
was a significant period of time following surgery for the
primary PA and the presence of a recurrent lesion (Fig. 6a,
Table 2). Using our nanoString-based 80-gene custom
codeset, we identified a subgroup of stemness genes that
were enriched in recurrent adenomas compared to their
matched primary tumors (Fig. 6b, n = 4, PA 23, 24, 25, 26).
Of particular interest was the increased expression of
components of developmental signaling pathway such as
Ptch1 and Axin2, implicating the activation of these tar-
gets in driving PA recurrence. In order to validate CD15
as a clinically applicable marker of PAICs, we performed
in silico analyses on a non-overlapping cohort of PAs for
which gene expression profiles were curated for non-
malignant pituitary glands, primary adenomas, and their
recurrent tumors [16] (Fig. 6c). CD15 expression was able
to discriminate between adenomas and normal pituitary
specimens and was elevated in recurrent adenomas when
compared to primary tumors (Fig. 6d).
Despite the enhanced expression of CD15 within re-
current adenomas on gene expression profiling, routine
clinical neuropathology is primarily based on immuno-
histochemical staining. Recent work with molecular
subgroups for pediatric brain tumors have attempted to
distill the diagnosis of these clinically-relevant subgroups
into cost-effective methods that may be readily introduced
in both academic and non-academic settings [18, 34]. We
therefore, performed CD15 immunostaining on a primary
and matched recurrent PA as a proof of principle in
describing the clinical utility of a putative PAIC marker.
There was a substantial increase in CD15 expression within
the recurrent tumor relative to the primary (Fig. 5e, f), illus-
trating the importance of combining functional in vitro and
in vivo studies with novel technological platforms so that
high resolution gene expression profiling may be easily
translated to routine clinical immunostaining. Although, it
is important to recognize CD15 enrichment in recurrent
adenomas may also be due to the survival of proliferating
cells or invasion of CD15+ non-resected adenoma cells.
Collectively, CD15 identifies a unique population of PAICs
that may drive tumor maintenance and eventual recurrence
in response to multiple developmental signaling pathways.
Discussion
Our work describes the first non-biased differential
stemness gene expression profiling of human PAs com-
plemented by functional in vitro self-renewal assays in
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support of a rare PAIC population. Through prospective
flow cytometric cell sorting for CD15, we have identified
an enhanced in vitro secondary sphere formation rate
within CD15+ cells, which was reinforced by a marked
increase in the turmor-initiating capacity of CD15+
PAICs compared to CD15- cells. The clinical relevance
of these findings was made apparent through in silico
analyses, gene expression profiling, and a retrospective
cohort of patient samples immunostained for CD15,
which collectively validated CD15 as a marker enriched
in recurrent adenomas. In performing this work, we
have overcome the technical limitations of culturing
primary human PAs and applied our framework for in-
vestigating the biological and clinical significance of rare
TICs.
Much of the literature pertaining to PAICs has
been driven by work done in transgenic mouse
models [1, 5, 7, 10, 33]. While several interesting ob-
servations have been made to support the derivation
of PAs from targeted mutations in putative pituitary
stem cell populations, the resulting lesions have also
been shown to resemble human adamantinomatous
craniopharyngioma [7]. In other instances, PAs derived
from murine models have not fully recapitulated the
hormonal heterogeneity seen in human tumors and may
therefore, inadequately represent the heterogeneous cell
populations that are responsible for initiating and main-
taining human PAs [5, 10, 33]. The recent description of
Sox2+ murine pituitary stem cells with the potential for
multi-lineage differentiation and tumor propagation has
offered valuable insight into non-cell-autonomous regula-
tors of tumor growth since resulting tumors were devoid
of Sox2 expression [1]. However, the clinical utility of these
findings is limited since oncogenic β-catenin mutations
used to propagate adenomas from Sox2+ cells have not
been identified in human PAs [4]. Although transgenic
murine models of PA may not effectively represent human
adenomas, these models offer a homogenous critical mass
of tumor cells that is essential for characterizing rare PAICs
[5]. While, obtaining such a critical mass of cells required
to perform repeated analyses has been a major limitation in
previous human studies [3, 19, 35, 36] and in our current
Fig. 5 CD15+ pituitary adenoma-initiating cells promote multi-lineage specification in vivo. Representative immunostains from PA22 CD15+ xenografts
(left panel) and corresponding PA22 patient tissue (right panel). Diffuse positivity for (a) synaptophysin and (b) CD56 indicating neuroendocrine origin
of tumor cells. c Desmin and (d) myogenin reactivity seen exclusively in xenografts suggesting multi-lineage specification for CD15+ PAICs. e Cytokeratin
(AE1/AE3) reactivity present in patient tissue but absent in xenograft indicating possible clonal divergence in xenograft. All images are at magnification
×200. Scale bare = 100μm
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work, the use of non-renewable, minimally-cultured,
patient-derived cells offers a model that is most in keeping
with human adenomas. Technical limitations in culturing,
maintaining, and expanding human patient-derived pituit-
ary adenoma cells will need to be overcome in future
studies so that the proof-of-principle CD15+ sorted in vivo
experiments achieved in our work may be further charac-
terized and validated. The effects of culture conditions in
predisposing PAICs to certain cell lineages should also be
considered when interpreting the multi-lineage differenti-
ation potential observed in xenografts generated from
CD15+ PAICs. We recognize the overrepresentation of
non-functioning adenomas in the current study as a
consequence of surgical bias pertaining to the most fre-
quently encountered pituitary adenoma subtype in our
neurosurgical department. Nevertheless, the identification
of a common PAIC for all subtypes provides the greatest
yield in terms of therapeutic efficacy as residual/recurrent
adenomas may be collectively targeted. Our work builds on
the TIC framework described in previous human studies by
providing a non-biased genetic screen for stemness, postu-
lating a developmental origin to the initiation and mainten-
ance of PAs, and functionally validating our findings in
both in vitro and in vivo assays at limiting dilutions.
Conclusion
The failure of current cancer therapeutics may be
attributed to a number of determinants such as clonal ex-
pansion based on cellular and genomic diversity, proper-
ties of stemness such as self-renewal, and the inability to
effectively prognosticate those patients who require more
aggressive upfront therapy. Our study provides a strategic
platform for the preclinical evaluation of these factors in
primary human PAs. Clinically, patients with CD15high
Fig. 6 CD15 expression is significantly enriched in recurrent pituitary adenomas. a Representative pre- and post-operative MRI of a primary and
matched-recurrent pituitary adenoma showing limited residual tumor following primary tumor resection and enhanced growth at recurrence. b
NanoString and (c) in silico gene expression data showing enrichment of stemness genes in recurrent adenomas as compared to primary tumors.
CD15 expression characterizes pituitary adenoma recurrence based on (b) NanoString and (d) in silico gene expression profiling. Representative
CD15 stain in (e) primary (×50) and (f) matched-recurrent (×50) pituitary adenoma identifying a substantial increase in CD15 expression at
tumor recurrence
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adenomas may benefit from more aggressive surgical
interventions and chemo/radiotherapy as future biological
studies should be focused on the identification of regula-
tory mechanisms that drive CD15+ PAICs to promote
tumor maintenance and disease recurrence. Such efforts
may reconceptualize the treatment of PA, a tumor that
continues to result in significant morbidity for a substan-
tial number of patients.
Additional file
Additional file 1: Representative flow cytometry plots of 3 pitutiary
adenoma samples showing Sox2 and CD15 expression. (TIFF 791 kb)
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